Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?

Effects of Food on Bioavailability of Lapatinib: Useful Data, Wrong Conclusion

(2009) Ian F. Tannock   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

(2009) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Capecitabine Monotherapy for Slowly Progressing Metastatic Breast Cancer: Do We Need Aggressive Treatment?

(2009) Marc Debled et al.   ONCOLOGY

Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer

(2008) C. Andreetta et al.   ANNALS OF ONCOLOGY

Novel Taxane Formulations in the Treatment of Breast Cancer: A Thought Leader Discussion and Consensus Roundtable

(2008) Julie Gralow et al.   Clinical Breast Cancer

A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression

(2008) N. Ribelles et al.   CURRENT DRUG METABOLISM

Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast Cancer

(2008) Tiffany A. Traina et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY

Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines

(2008) Daniel G. Haller et al.   JOURNAL OF CLINICAL ONCOLOGY